A PROSPECTIVE OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF TOPIRAMATE ALONE VERSUS TOPIRAMATE WITH VITAMIN D IN PROPHYLACTIC TREATMENT OF PATIENTS WITH MIGRAINE

Simple item page
dc.contributor.authorDIXIT, A.en_US
dc.contributor.authorBRAHEMI, M.en_US
dc.contributor.authorKHAN, N. F.en_US
dc.contributor.authorYADAV, R.en_US
dc.contributor.authorSINGH, C. Ven_US
dc.date.accessioned2025-08-13T08:56:14Z
dc.date.available2025-08-13T08:56:14Z
dc.date.issued2025-03
dc.description.abstractand sound sensitivity. While acute treatments are common, preventive therapies are underutilized. Recent studies suggest combining vitamin D with Topiramate, an anticonvulsant, could enhance prevention, reducing both attack frequency and duration. Therefore, the present study compares the safety and efficacy of Topiramate alone versus topiramate with Vitamin D. Methods: A study was conducted on 100 migraine patients to compare the effect of topiramate alone versus topiramate with vitamin D. Pain severity and disability were measured using a Visual Analog Scale (VAS), Migraine Disability Assessment Score (MIDAS), and Migraine Severity (MIGSEV) scores over 12 w, excluding patients with other medical conditions. Results: Both the Topiramate and Topiramate with Vitamin D groups showed significant reduction in VAS, MIDAS, and MIGSEV scores after 12 weeks. Migraine without aura was more common in both groups. The Topiramate with Vitamin D group also experienced increased serum calcium and Vitamin D levels. Both groups showed significant improvements in pain and disability, with the Topiramate with Vitamin D group showing better results. Conclusion: Combining topiramate with vitamin D effectively reduces migraine frequency and disability.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah. UP-206130, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, GMC, Budaun-243601, Uttar Pradesh, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, GSVM MC, Kanpur. UP-208002, Indiaen_US
dc.identifier.affiliationsDepartment of Neurology, University of Medical Sciences, Saifai, Etawah-206130, Uttar Pradesh, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah. UP-206130, Indiaen_US
dc.identifier.citationDIXIT A, BRAHEMI M, KHAN NF, YADAV R, SINGH CV.. A PROSPECTIVE OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF TOPIRAMATE ALONE VERSUS TOPIRAMATE WITH VITAMIN D IN PROPHYLACTIC TREATMENT OF PATIENTS WITH MIGRAINE. International Journal of Pharmacy and Pharmaceutical Sciences . 2025 Mar; 17(3): 32-35en_US
dc.identifier.issn0975-1491
dc.identifier.issn2656-0097
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/250294
dc.languageenen_US
dc.publisherInnovare Academic Sciences Pvt. Ltd.en_US
dc.relation.issuenumber3en_US
dc.relation.volume17en_US
dc.source.urihttps://doi.org/10.22159/ijpps.2025v17i3.53449en_US
dc.subjectPain severityen_US
dc.subjectMigraine disability assessment scoreen_US
dc.titleA PROSPECTIVE OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF TOPIRAMATE ALONE VERSUS TOPIRAMATE WITH VITAMIN D IN PROPHYLACTIC TREATMENT OF PATIENTS WITH MIGRAINEen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijpps2025v17n3p32.pdf
Size:
869.83 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Pharmacy and Pharmaceutical Sciences